Cabergolina [Spanish] en es it fr

Cabergolina [Spanish] Brand names, Cabergolina [Spanish] Analogs

Cabergolina [Spanish] Brand Names Mixture

  • No information avaliable

Cabergolina [Spanish] Chemical_Formula


Cabergolina [Spanish] RX_link

Cabergolina [Spanish] fda sheet

Cabergolina [Spanish] msds (material safety sheet)

Cabergolina [Spanish] Synthesis Reference

No information avaliable

Cabergolina [Spanish] Molecular Weight

451.604 g/mol

Cabergolina [Spanish] Melting Point

102 - 104 oC

Cabergolina [Spanish] H2O Solubility


Cabergolina [Spanish] State


Cabergolina [Spanish] LogP


Cabergolina [Spanish] Dosage Forms

Tablets for oral administration (0.5 mg)

Cabergolina [Spanish] Indication

For the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

Cabergolina [Spanish] Pharmacology

Cabergoline is a dopamine receptor agonist and uncategorized drug which suppresses the production of prolactin in pituitary gland. It is an ergot-derivative. It has at times been used as an adjunct to SSRI antidepressants as there is some evidence that it counteracts certain side effects of those drugs such as reduced libido and anorgasmia. It also has been suggested online that it has a possible recreational use in reducing or eliminating the male refractory period.

Cabergolina [Spanish] Absorption

First-pass effect is seen, however the absolute bioavailability is unknown.

Cabergolina [Spanish] side effects and Toxicity

Overdosage might be expected to produce nasal congestion, syncope, or hallucinations.

Cabergolina [Spanish] Patient Information

Cabergolina [Spanish] Organisms Affected

Humans and other mammals